Curated News
By: NewsRamp Editorial Staff
March 14, 2025
Kamada Ltd. Sets New Financial Records in 2024, Eyes Further Growth in 2025
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- Kamada Ltd gains an edge with plasma-derived medicines, achieving record-breaking financial performance in 2024.
- Plasma is the largest component of human blood, critical for developing specialty therapies that fight diseases.
- Kamada's plasma-derived therapeutics offer hope to patients with rare diseases, aiming for continued growth to help more people.
- Kamada's expansion into biosimilar launches and clinical trials offers exciting opportunities in the plasma-based therapeutics market.
Impact - Why it Matters
This news matters as it highlights Kamada's success in the plasma-derived therapeutics market, showcasing its ability to address critical medical needs. The company's strong financial performance and expansion plans indicate a promising outlook for providing innovative treatments for rare diseases.
Summary
Kamada Ltd. achieves record-breaking financial performance in 2024, posting substantial revenue growth and operational efficiency. The pharmaceutical innovator specializes in plasma-derived therapeutics, offering solutions for rare and serious diseases. Kamada forecasts continued double-digit growth and expansion efforts in global markets for 2025.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Kamada Ltd. Sets New Financial Records in 2024, Eyes Further Growth in 2025
